SOUTH SAN FRANCISCO, Calif.,
Jan. 7, 2021 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the 39th Annual J.P. Morgan Virtual Healthcare
Conference on Thursday, January 14,
2021 at 10:00 a.m. Eastern
Time.
To access the live and subsequently archived webcast, go to the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with hematologic
disorders, cancer and rare immune diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib1 is currently being studied in a Phase 3
trial for the treatment of warm autoimmune hemolytic anemia (AIHA);
an NIH/NHLBI-sponsored Phase 2 trial for the treatment of
hospitalized COVID-19 patients, in collaboration with Inova Health
System; and a Phase 2 trial for the treatment of COVID-19 being
conducted by Imperial College London. Additionally, Rigel launched
a Phase 3 clinical trial of fostamatinib for the treatment of
hospitalized COVID-19 patients.
Rigel's other clinical programs include an ongoing Phase 1 study
of R8351, a proprietary molecule from its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a recently
completed Phase 1 study of R5521, a proprietary molecule
from its receptor-interacting serine/threonine-protein kinase
(RIPK) inhibitor program. In addition, Rigel has product candidates
in clinical development with partners AstraZeneca, BerGenBio ASA,
and Daiichi Sankyo.
Please see www.TAVALISSE.com for full Prescribing
Information.
1 The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301202534.html
SOURCE Rigel Pharmaceuticals, Inc.